Monday, November 9, 2026
Market

Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could triple

By: admin

Date:

access pro

Deutsche Bank backs AtaiBeckley in the Psychedelic Renaissance, citing drugs BPL-003, VLS-01 and EMP-01 and projecting multibillion dollar sales after FDA approval.

Deutsche Bank believes AtaiBeckley is well-positioned to be a winner in the “Psychedelic Renaissance.”

Continue Reading with
CNBC-TV18 Access Membership

Priority Access and Networking: CNBC-TV18’s flagship events

Interaction with CNBC-TV18’s journalists

Webinars & LIVE Q&As with India Inc. Leaders

Exclusive CNBC-TV18 studio & newsroom tours

Premium business insights, expert opinions & analysis

Curated lifestyle privileges & offers

Source link

Previous article
Gold, silver rates today: Comex gold drops $233/oz; silver falls $6.4/oz as Trump signals escalation in Iran conflict
Next article
West Asia War: Tech infrastructure as the new battlefield
admin
admin

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

‘Trump has cost us’: After midterm losses, MAGA asks if it’s over

admin admin -
As Republicans faced a nationwide drubbing in Tuesday’s midterm...

Prashant Jain sees 12-15% annual returns from Indian equities over 3-5 years

admin admin -
Question We've had a very painful period for the equity...

Raamdeo Agrawal sees FIIs return as earnings improve and valuations turn attractive

admin admin -
Question Looking at the valuation compression across the market, are...

Stocks to Watch for November 2: Reliance Industries, Jio Platforms, BEL, Vodafone Idea, IOC, M&M and more

admin admin -
From Reliance Industries and Jio Platforms reporting strong quarterly...
© 2025 JMD Associates. All Rights Reserved. Partnered with Master Trust for Comprehensive Investment Solutions.